Programmable repair starts at the epithelial surface
Galvanis develops topical therapies that tune endogenous bioelectric signals in impaired ocular surface healing.
OUR MODEL
Find a repair setting with a measurable signal
Quantify TEP and ion-flux changes where epithelial closure can be read objectively.Modulate the signal without implanted hardware
Use topical candidates to adjust endogenous ion transport during the repair window.Advance only on linked evidence
A lead must shift PD, improve closure ex vivo, and reproduce the effect in vivo before additional spend.
The first application is persistent corneal epithelial defects, where closure is visible, time-to-signal is short, and unresolved defects can push patients toward procedural care.
Epithelial tissues maintain voltage gradients and directional ion flux. When the corneal surface is injured, the circuit is locally interrupted; the surrounding epithelium drives current and electric fields toward the defect.
Galvanis uses ΔTEP and Δion flux as pharmacodynamic readouts. The therapeutic question is not whether bioelectricity exists. The question is whether a topical candidate can move the signal and shorten closure time in the same model.
The repair signal can be measured
We do not advance a molecule because it looks active in a single closure assay. We advance when a candidate produces a measurable PD shift and that shift travels with functional closure across models.
Run repair biology like a gated development system
PCED is the beachhead because the defect is visible, closure is objective, topical dosing is local, and failed closure can escalate quickly.
Objective endpoint
Closure can be measured directly with standard ocular-surface imaging.High unmet need
Persistent defects are rare, serious, and difficult to manage when conventional care fails.Local delivery
The corneal surface supports high local exposure with limited systemic burden.Rapid translational loop
In vitro, ex vivo, and in vivo models can connect PD to closure before a large clinical program.
Start where the biology can be read cleanly
Prove the PD-to-closure link in PCED, then apply the same assay logic to adjacent impaired-healing ocular surface settings.
Focused wedge to repair franchise
How we decide what earns the next dollar
North star metrics: one product hypothesis, three gates
2026 execution focus
Raise $2.5M SAFE to run a six month, milestone‑gated plan.
Downselect PD‑validated lead by week 14.
File provisionals (composition + methods + assays).
Non-GLP rabbit model at week 14 screening two lead candidates.
IP/FTO gated lead, rabbit closure data, no tolerability red flags, and a seed-ready diligence package by week 24.
Align with the vision
If you’re an investor or clinical partner who believes in regenerative medicine, we should talk.